Statista, a global data company that publishes insights for 170 industries, projects four cancer therapies will be among the top 10 best-selling pharmaceutical products in the U.S. this year.
The company projects Merck’s cancer drug Keytruda will earn $12.7 billion in U.S. revenue in 2026 — nearly twice that of the second top-selling medication, according to data shared March 9 with Becker’s.
Here are the medications Statista projects will be the 10 best-selling U.S. pharmaceutical products in 2026:
1. Keytruda — $12.7 billion
Manufacturer: Merck
FDA-approved for about a dozen cancers, including non-small cell lung cancer and melanoma
2. Biktarvy — $8.2 billion
Manufacturer: Gilead Sciences
FDA-approved as an HIV-1 treatment
3. Eliquis — $7.8 billion
Manufacturer: BMS
FDA-approved as a blood thinner medicine to reduce blood clotting
4. Imbruvica — $6.7 billion
Manufacturer: AbbVie
FDA-approved for several blood cancers and chronic graft-versus-host disease
5. Dupixent — $6.4 billion
Manufacturer: Sanofi
FDA-approved for nine chronic inflammatory conditions, including chronic obstructive pulmonary disease
6. Opdivo — $6.1 billion
Manufacturer: BMS
FDA-approved for more than a dozen cancers, including melanoma and renal cell carcinoma
7. Ozempic — $6 billion
Manufacturer: Novo Nordisk
FDA-approved for Type 2 diabetes, cardiovascular disease and kidney disease
8. Trikafta — $6 billion
Manufacturer: Vertex
FDA-approved for cystic fibrosis
9. Ocrevus — $5.9 billion
Manufacturer: Roche
FDA-approved for multiple sclerosis
10. Ibrance — $5.9 billion
Manufacturer: Pfizer
FDA-approved for breast cancer
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.